Clinical Trial ProgressThe initiation, enrollment, and dosing of CT-95 in trials are seen positively, especially since it was licensed by the company recently.
Financial StabilityContext remains well-capitalized with $94.4M in cash, providing financial stability and runway into 2027.
ValuationAnalyst believes Context is undervalued based on the potential of its three wholly owned TCEs, suggesting a buying opportunity.